Sonoma Pharmaceuticals Files 8-K

Ticker: SNOA · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1367083

Sentiment: neutral

Topics: 8-k, disclosure, financials

TL;DR

Sonoma Pharma dropped an 8-K on April 2nd, check the financials and disclosures.

AI Summary

Sonoma Pharmaceuticals, Inc. filed an 8-K on April 2, 2024, reporting on Regulation FD disclosures and financial statements/exhibits. The company, formerly Oculus Innovative Sciences, Inc., is incorporated in Delaware and headquartered in Boulder, Colorado.

Why It Matters

This filing provides important updates and disclosures regarding Sonoma Pharmaceuticals' regulatory compliance and financial reporting.

Risk Assessment

Risk Level: low — This is a routine filing for regulatory and financial disclosures, not indicating immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific items are being disclosed in this 8-K filing?

This 8-K filing specifically covers Regulation FD Disclosure and Financial Statements and Exhibits.

When was Sonoma Pharmaceuticals, Inc. previously known by another name?

The company was formerly known as Oculus Innovative Sciences, Inc., with a name change date of June 22, 2006.

Where are Sonoma Pharmaceuticals, Inc.'s principal executive offices located?

The principal executive offices are located at 5445 Conestoga Court, Suite 150, Boulder, CO 80301.

What is the fiscal year end for Sonoma Pharmaceuticals, Inc.?

The fiscal year end for Sonoma Pharmaceuticals, Inc. is March 31.

What is the SIC code for Sonoma Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for Sonoma Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 752 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2024-04-02 07:30:16

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the "Company"). The presentation materials are furnished hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the Company. These forward-looking statements are identified by the use of words such as "will," "develop," "project," "expect," and "expand," among others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Investor Presentation as of April 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). _______________ The information filed as Exhibit 99.1 to this Current Report on Form 8-K is being furnished in accordance with Item 7.01 and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities imposed by that Section. Such information shall not be incorporated by reference into any registration statement or other document or filing under the Securities Act of 1933, as amended, except as may be expressly set forth in a specific filing. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: April 2, 2024 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing